- Home
- JXG vs SNGX Comparison
JXG vs SNGX Comparison
Compare JXG & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- SNGX
- Stock Information
- Founded
- JXG N/A
- SNGX 1987
- Country
- JXG China
- SNGX United States
- Employees
- JXG N/A
- SNGX N/A
- Industry
- JXG
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- SNGX Health Care
- Exchange
- JXG Nasdaq
- SNGX Nasdaq
- Market Cap
- JXG 16.9M
- SNGX 13.8M
- IPO Year
- JXG N/A
- SNGX 1987
- Fundamental
- Price
- JXG $0.51
- SNGX $1.38
- Analyst Decision
- JXG
- SNGX Strong Buy
- Analyst Count
- JXG 0
- SNGX 1
- Target Price
- JXG N/A
- SNGX $6.00
- AVG Volume (30 Days)
- JXG 216.1K
- SNGX 258.1K
- Earning Date
- JXG 12-05-2025
- SNGX 11-07-2025
- Dividend Yield
- JXG N/A
- SNGX N/A
- EPS Growth
- JXG N/A
- SNGX N/A
- EPS
- JXG 0.35
- SNGX N/A
- Revenue
- JXG $46,835,624.00
- SNGX N/A
- Revenue This Year
- JXG N/A
- SNGX N/A
- Revenue Next Year
- JXG N/A
- SNGX N/A
- P/E Ratio
- JXG $1.52
- SNGX N/A
- Revenue Growth
- JXG 21.68
- SNGX N/A
- 52 Week Low
- JXG $0.48
- SNGX $1.09
- 52 Week High
- JXG $6.12
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- JXG 25.18
- SNGX 41.43
- Support Level
- JXG $0.55
- SNGX $1.25
- Resistance Level
- JXG $0.59
- SNGX $1.41
- Average True Range (ATR)
- JXG 0.06
- SNGX 0.10
- MACD
- JXG -0.01
- SNGX 0.02
- Stochastic Oscillator
- JXG 9.76
- SNGX 41.84
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).